Quinoxalinyl derivatives
    27.
    发明授权
    Quinoxalinyl derivatives 有权
    喹喔啉衍生物

    公开(公告)号:US08962551B2

    公开(公告)日:2015-02-24

    申请号:US12327538

    申请日:2008-12-03

    摘要: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

    摘要翻译: 本发明涉及式I或II的化合物或其药学上可接受的盐,酯或前药:其抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒(HCV)NS3-NS4A蛋白酶的活性。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Arylalkoxyl hepatitis C virus protease inhibitors
    28.
    发明授权
    Arylalkoxyl hepatitis C virus protease inhibitors 失效
    芳酰基甲酰丙型肝炎病毒蛋白酶抑制剂

    公开(公告)号:US07687459B2

    公开(公告)日:2010-03-30

    申请号:US11836288

    申请日:2007-08-09

    IPC分类号: A61K38/12 A61K38/06 A61K39/42

    摘要: The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

    摘要翻译: 本发明公开了式I或II的化合物或其药学上可接受的盐,酯或前药:其抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒(HCV)NS3-NS4A蛋白酶的活性。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过向受试者施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
    29.
    发明申请
    AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
    AZA-TRIPEPTIDE HEPATITIS C丝氨酸蛋白酶抑制剂

    公开(公告)号:US20080287449A1

    公开(公告)日:2008-11-20

    申请号:US12108647

    申请日:2008-04-24

    摘要: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译: 本发明涉及抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒(HCV)NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐,酯或前药。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。